ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RLX-2508

A development code.

Its studies are mostly in Influenza, Human, led by Jiangsu HengRui Medicine.

Furthest: early phase 1, since Oct 8, 20261 company-led study, 1 open or runningNext primary completion: Jan 30, 2029 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningearly phase 1since Oct 8, 2026Oct 8, 2026Jan 30, 2029early phase 1 · NCT07873671

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2026First study: early phase 1 study in Influenza, HumanFirst studyNCT07873671 · 101 planned · Australia

Ahead

  1. Jan 30, 2029Primary completion: early phase 1 study in Influenza, HumanNCT07873671

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07873671Influenza, Human · AustraliaEarly 1Not yet recruitingJan 30, 2029101

How it is read

Names in the registry

  • “RLX-2508”, 4 entries

Codes read as this program: RLX2508.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.